Ambien CR launch takes hold

Share this article:
A controlled release version of the Sanofi-Aventis anti-insomnia drug zolpidem, Ambien CR has reached pharmacy shelves, the company said.
The new pill, launched October 7, is being introduced to doctors by a force of 3,500 sales reps, the firm noted.
Sanofi-Aventis is hoping CR receives a warm welcome, as top-selling Ambien is set to move off patent next year. Brand communications emphasize its indication for sleep maintenance, as well as sleep induction. Publicis' Saatchi & Saatchi family of agencies handles med ed, consumer and professional ads.
Ambien had U.S. third-quarter sales of 371 million euros ($437 million), up 4.8% from the same quarter last year, according to the drug maker. U.S. sales for the nine months ending in September reached 948 million euros ($1.1 billion), an increase of 8.8%.
The Ambien franchise faces competition from two other recently launched prescription sleep aids, Rozerem (ramelteon) from Takeda Pharmaceuticals North America and Sepracor's Lunesta (eszopiclone).
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Channel

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...